Beyond Standard Renoprotection: Palm Tocotrienol-Rich Vitamin E and Multi-Hit Residual Renal Risk in Diabetic Kidney Disease-A Translational Review

Abstract

Diabetic kidney disease (DKD) remains a major cause of chronic kidney disease, kidney failure, cardiovascular morbidity, and premature mortality despite substantial advances in renoprotective therapy. Sodium–glucose cotransporter-2 inhibitors, renin–angiotensin-system blockade, nonsteroidal mineralocorticoid-receptor antagonists, glucagon-like peptide-1 receptor agonists, and increasingly multidrug cardiorenal strategies have transformed DKD management, yet clinically meaningful residual renal risk persists.

Palm-derived tocotrienol-rich vitamin E is of translational interest because it may influence oxidative, inflammatory, endothelial, metabolic, mitochondrial, and potentially fibrotic pathways that remain active during DKD progression. Direct human evidence, however, is preliminary. A Phase IIb randomized trial reported improvements in serum creatinine and estimated glomerular filtration rate, particularly in stage 3 chronic kidney disease, without corresponding improvement in albuminuria, and the apparent filtration benefit disappeared after treatment withdrawal. This qualitative review critically integrates contemporary DKD pathobiology, modern pharmacological renoprotection, tocotrienol pharmacology, randomized human evidence, and the discrepancy between filtration- and albuminuria-based endpoints.